UPDATE: Benchmark Company Initiates Coverage on LeMaitre Vascular on Multiple Positive Factors

In a report published Thursday, Benchmark Company analyst Jan Wald initiated coverage on LeMaitre Vascular (NASDAQ: LMAT) with a Buy rating and $9.00 price target.

In the report, Benchmark Company noted, “We are initiating coverage on LeMaitre Vascular with a Buy rating and a $9 price target. We believe that the company's well-established position within the vascular surgeon community, and its focus on niche products that typically do not attract competition from the industry giants, give the company a bit of a home field advantage. We believe they are capitalizing on this opportunity. Its growth strategy has relied heavily on small tuck-in acquisitions, and we believe that in the coming years the company could become more open to larger deals which could open up more markets within its core competencies. We believe 10%+ annual revenue growth and a $0.12 annual dividend provides investors with reasons to own the stock ahead of any moves to a more Street-friendly facing.”

LeMaitre Vascular closed on Wednesday at $6.97.